AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00644852 — intervention group
Intervention type: OTHER
Intervention: Retrospective chart review study
Description: Retrospective study chart review long acting risperidone
Study NCT04127630 — intervention group
Intervention type: PROCEDURE
Intervention: mobilization of the larynx
Description: we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
Study NCT00299286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle.
Study NCT00299286 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lapatinib-Placebo
Description: In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose.
Study NCT01090752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Study NCT01090752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
Study NCT05174195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.075 milligram
Description: Inserted after 3 months use of DESOGESTREL
Study NCT05174195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Implanon NXT® subdermal implant
Description: Inserted immediately
Study NCT05174195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Implanon NXT® subdermal implant
Description: Inserted immediately
Study NCT01635283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor lysate-pulsed autologous dendritic cell vaccine
Description: Given ID
Study NCT01635283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03115268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support groups delivered in EVA Park
Description: Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
Study NCT03115268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social support groups delivered in EVA Park
Description: Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib 110 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Almonertinib.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying EGFR mutations will be administrated with Dacomitinib.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib 150 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion will be administrated with Alectinib.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation will be administrated with Crizotinib.
Study NCT00950391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
Study NCT04309305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EksoGT™, Ekso Bionics, Berkley, CA, USA
Description: The Robotic Exoskeleton is a device that will be strapped to the chest and legs and worn over the shoulders like a backpack that will assist in walking.
Study NCT04309305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard gait therapy provided by licensed physical therapists post stroke.
Study NCT04309305 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Testing Only
Study NCT03729037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR self-training
Study NCT03729037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR self-training
Study NCT02083848 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 7T MRI
Description: Ultra high field magnetic resonance imaging
Study NCT03350256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Description: BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
Study NCT01478685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
Study NCT01478685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
Study NCT01478685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m\^2
Study NCT03354312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 1% Gel
Description: Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
Study NCT03354312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine hydrochloride/epinephrine (adrenaline) hydrochloride
Description: Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
Study NCT00914446 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: hepatic biopsies
Description: hepatic biopsies
Study NCT00571870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrorelix acetate
Description: The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
Study NCT00571870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetrorelix acetate
Description: The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
Study NCT05587062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept (CinnaGen Co, Iran)
Description: Aflibercept (CinnaGen Co, Iran) by intravitreal injection
Study NCT05587062 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept (Regeneron, USA)
Description: Aflibercept (Regeneron, USA) by intravitreal injection
Study NCT02185573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bulk fill
Description: This is one of the composite restoration application techniques
Study NCT02185573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SonicFill
Description: This is the recent intervention under evaluation
Study NCT04278768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib is formulated as a tablet for oral administration for BID dosing in consecutive 28-day cycles. Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 kinase plays an essential role in toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways and these pathways are frequently dysregulated in non-Hodgkin's lymphoma and AML/MDS malignancies.
Study NCT02709785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse
Description: Subjects use chlorhexidine mouth rinse for six weeks.
Study NCT02709785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rinse
Description: Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib 160/80 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying HER-2 mutation or HER-2 over expression/amplification will be administrated with Pyrotinib.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying CKIT mutation will be administrated with Imatinib.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200/300 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying BRCA1/2 mutation will be administrated with Olaparib.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Patients with advanced rare tumors who failed to standardized treatment carrying CDKN2A mutation will be administrated with palbociclib.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib 240 MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying BRAF mutation will be administrated with Vemurafenib.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab 100MG
Description: Patients with advanced rare tumors who failed to standardized treatment carrying no targeted alterations will be administrated with Sintilimab.
Study NCT04423185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1680 MG
Description: Patients with BRAF mutation treated with vemurafenib, after acquired resistance, will combine vemurafenib with atezolizumab.
Study NCT00010374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuRx DPS
Description: Laparoscopic implantation of diaphragm electrodes and subsequent pacing with the NeuRx DPS.
Study NCT04278768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Ventoclax is B-cell lymphoma-2 (BCL-2) inhibitor. Venetoclax will be administered at 100 mg orally (Day 1) per the product label at the same time each day with a ramp up over 3 days to 400 mg for 21days of a 28-day Cycle. Second and subsequent cycles start with target dose level.
Study NCT01679717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early mobilisation after CMC1-surgery
Description: Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
Study NCT01679717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilisation after CMC1-surgery
Description: Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
Study NCT00905710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Description: Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
Study NCT01354379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NB-1008
Description: NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
Study NCT01354379 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone IN
Description: The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
Study NCT02905747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Exercise Therapy
Description: physiotherapy intervention with Medical exercise therapy (MET) during 3 months
Study NCT00706862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin
Description: Oral, 1.5 grams twice per day
Study NCT00706862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, twice per day
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Given PO
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Given PO
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, SC
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, IV, SC
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated L-Asparaginase
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated L-Asparaginase
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT, IV, PO
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, PO
Study NCT03150693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT03150693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT03150693 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study NCT03150693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT03150693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT03150693 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03150693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01680003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepar-P
Study NCT01680003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Hepar-P
Study NCT03937843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
Study NCT03937843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day.
Study NCT03937843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Patients in cohort 2 will receive on day 1 to day 5:~* a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~* a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day.
Study NCT02714426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-inspired treatment
Description: Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
Study NCT04278768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib is formulated as a tablet for oral administration for BID dosing for 21 days (Days 1-21) of a 28-day Cycle.
Study NCT00883545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Woman endoscopist
Description: This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
Study NCT00883545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
Study NCT02959541 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin
Study NCT02943330 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
Study NCT02543866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation